Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kumar Prabhash

Showing results (341-350 of 469) with videos related to

Pageof 47
Sort By:
Exploration of Targeted Anti-Tumor Therapy|September 25, 2023
Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancerAbhishek Mahajan, Gurukrishna B, Shweta Wadhwa, et al.
Journal of Global Oncology|July 19, 2017
Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung CancerVijaya Raj Bhatt, Sanyo P D'Souza, Lynette M Smith, et al.
Chemotherapy Research and Practice|December 5, 2017
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?Amit Joshi, Vanita Noronha, Vijay M Patil, et al.
The Lancet. Oncology|January 15, 2024
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trialJyoti Bajpai, Venkatesh Kapu, Sushmita Rath, et al.
South Asian Journal of Cancer|March 24, 2025
Efficacy and Safety of Low-Dose Nivolumab in Treatment of Advanced Solid Tumors: A Retrospective Audit from Resource-Constrained SettingsAmit Kumar, Akhil Kapoor, Vanita Noronha, et al.
Indian Journal of Cancer|April 6, 2019
Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in IndiaGagan Prakash, Mahendra Pal, K Odaiyappan, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT ImagingAbhishek Mahajan, Rajat Agarwal, Ujjwal Agarwal, et al.
Clinical Lung Cancer|August 12, 2024
Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer PatientsPrerana Jha, Asim Joshi, Rohit Mishra, et al.
ESMO Open|August 2, 2017
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
Cancer Medicine|February 16, 2021
A real-world data of Immune checkpoint inhibitors in solid tumors from IndiaVanita Noronha, George Abraham, Vijay Patil, et al.
Pageof 47

Showing results (341-350 of 469) with videos related to

Sort By:
Pageof 47
Exploration of Targeted Anti-Tumor Therapy|September 25, 2023
Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancerAbhishek Mahajan, Gurukrishna B, Shweta Wadhwa, et al.
Journal of Global Oncology|July 19, 2017
Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung CancerVijaya Raj Bhatt, Sanyo P D'Souza, Lynette M Smith, et al.
Chemotherapy Research and Practice|December 5, 2017
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?Amit Joshi, Vanita Noronha, Vijay M Patil, et al.
The Lancet. Oncology|January 15, 2024
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trialJyoti Bajpai, Venkatesh Kapu, Sushmita Rath, et al.
South Asian Journal of Cancer|March 24, 2025
Efficacy and Safety of Low-Dose Nivolumab in Treatment of Advanced Solid Tumors: A Retrospective Audit from Resource-Constrained SettingsAmit Kumar, Akhil Kapoor, Vanita Noronha, et al.
Indian Journal of Cancer|April 6, 2019
Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in IndiaGagan Prakash, Mahendra Pal, K Odaiyappan, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT ImagingAbhishek Mahajan, Rajat Agarwal, Ujjwal Agarwal, et al.
Clinical Lung Cancer|August 12, 2024
Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer PatientsPrerana Jha, Asim Joshi, Rohit Mishra, et al.
ESMO Open|August 2, 2017
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinomaVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
Cancer Medicine|February 16, 2021
A real-world data of Immune checkpoint inhibitors in solid tumors from IndiaVanita Noronha, George Abraham, Vijay Patil, et al.
Pageof 47